Industry Verticals »

All Categories

Insights »

About TMR »

Myasthenia Gravis Market

Myasthenia Gravis Market (Treatment- Drug Treatment (Cholinesterase Inhibitors, Monoclonal Antibodies, and Chronic Immunomodulators) and Rapid Immunotherapies (Plasmapheresis, Intravenous Immunoglobulin (IVlg), and Thymectomy)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global myasthenia gravis market for the historical period 2018–2019 and forecast period 2020–2030, high prevalence of autoimmune diseases and strong focus on introducing new therapies is augmenting the growth of global market. Moreover, improving healthcare infrastructure is likely boost the growth of market during the forecast period.
  • According to the report, the market was valued at US$ 1.2 Bn in 2018 and is anticipated to expand at a CAGR of 8.0% from 2019 to 2027
fa global myasthenia gravis market

To know the scope of our report Get a Sample

Rise in Focus on Research & Development and Increase in Prevalence of Autoimmune Disorder: Key Drivers of Global Myasthenia Gravis Market

  • Autoimmune disorder is a condition of immune system in which the body's immune system attacks healthy cells. It is most common in the older men (over 60) and young adult women (under 40). Hence, increase in geriatric population is a key factor likely boost the growth of market. For instance, according to Cancer Facts & Figures 2019, estimated number of older adults age 85 years and above was 6.4 million in 2016 and it is expected to reach 19.0 million by 2060
  • Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that affects voluntary muscles. According to the Myasthenia Gravis Foundation of America, around 20 in 100,000 people in the U.S. are diagnosed with myasthenia gravis each year
  • Myasthenia gravis is a rare disease without a definite cure, however it can be treated with medications, surgeries, and other therapies alone or in combination. This is augmenting the demand for new therapies and medications, which is driving key players operating in the market to invest in the research and development and develop new therapies. For instance, Rozanolixizumab (UCB7665) is a humanized anti-human neonatal Fc receptor (FcRn) monoclonal antibody designed to reduce the levels of pathogenic IgG in autoimmune diseases. It is in clinical trial phase for reducing the levels of pathogenic IgG in autoimmune diseases and myasthenia gravis. Strong pipeline and introduction of new therapies are the factors likely boost the growth of market

Get a glimpse of the in-depth analysis through our Report Brochure

Increase in Healthcare Infrastructure Propel Global Myasthenia Gravis Market Growth

  • Increase in health care expenditure coupled with rise in global per capita income is anticipated to drive demand for costly treatments such as plasma exchange and intravenous immunoglobulin (IVIG) therapies
  • Moreover, governments in developing countries are making significant investments toward modernization of health care infrastructure, which is likely to increase access to health care. This is expected to increase in the demand for advance technologies, therapies and treatments. This is leading to create opportunities in the monoclonal antibodies and IVIG treatments in the market in the near future

Expensive Treatment Options to Hamper Global Myasthenia Gravis Market

  • Discovery and development of new therapeutics incurs high cost and takes longer time for commercialization. The never approved therapies with IVIG and monoclonal antibodies are expensive treatment options. The cost of plasma collection and manufacturing processes for IVIG products is high as compared to the materials and processes used in the manufacture of traditional pharmaceutical products. Moreover, being a blood derived component, highly sophisticated collection, purification, and storage methods are required for intravenous immunoglobulin (IVIG) products.
  • Plasmapheresis and thymectomy are costly in comparison to symptomatic drug therapy which additionally need hospitalization. Cost is major factor that influence the selection of treatment which is anticipated to hamper the growth of global myasthenia gravis treatment market.

Chronic Side Effects: Restrain of Global Myasthenia Gravis Market

  • Side effects associated with intravenous immunoglobulin (IVIG) preparations could present serious health problems in some patients. Some of the side effects associated with intravenous immunoglobulin (IVIG) are flushing, muscle cramps, chills, fever, nausea, vomiting, back/joint pain, chest pain, sudden cough, wheezing, or shortness of breath.
  • These side effects can sometimes force a patient to discontinue the therapy which are leading to restrain the global market.

Competitive Landscape

  • This report profiles major players in the global market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global myasthenia gravis market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global market are
    • Alexion Pharmaceutical Inc.
    • Avadel Pharmaceuticals, PLC. (Flamel Technologies)
    • CSL Behring
    • Grifols, S.A.
    • Baxter International, Inc.
    • Shire plc
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Takeda Pharmaceutical Company Limited
    • Valeant Pharmaceuticals International, Inc.

Expanding operations in future? To get the perfect launch ask for a custom report 

Key Developments

Key players in the global myasthenia gravis market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global market. A few expansion strategies adopted by players operating in the global market are:

  • In October 2019, Ra Pharmaceuticals Inc. and UCB entered into merger agreement in which UCB acquired Ra Pharma to enhanced the treatment option for the people living with myasthenia gravis and other rare diseases
  • In January 2018, Alexion’s Soliris launched with new myasthenia gravis indication
  • in October 2017, Alexion Pharmaceuticals, Inc. received the FDA approval for use of Solaris in the treatment of generalized myasthenia gravis

The report on the global myasthenia gravis market discussed individual strategies, followed by company profiles of manufacturers of myasthenia gravis. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global market.

Global Myasthenia Gravis Market - Segmentation

Treatment Type
  • Drug Treatment
    • Cholinesterase Inhibitors
    • Chronic Immunomodulators
    • Monoclonal Antibodies
  • Rapid Immunotherapies
    • Plasmapheresis
    • Intravenous Immunoglobulin (Ivlg)
    • Thymectomy

Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of myasthenia gravis market?

Myasthenia gravis market is expected to reach US$ 2.4 Bn By 2027

What is the anticipated CAGR of the myasthenia gravis market in the forecast period?

Myasthenia gravis market is anticipated to expand at a CAGR of 8.0% from 2019 to 2027

What are the key driving factors for the growth of the myasthenia gravis market?

Myasthenia gravis market is driven by high prevalence of autoimmune diseases and strong focus on introducing new therapies

Which region is expected to project the highest market share in the global myasthenia gravis market?

North America accounted for major share of the global myasthenia gravis market and the trend is anticipated to continue during the forecast period

Who are the key players in the global myasthenia gravis market?

Key players in the global myasthenia gravis market include Alexion Pharmaceutical Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies), CSL Behring, Grifols, S.A.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Myasthenia Gravis Market 

    4. Market Overview

        4.1. Introduction

            4.1.1. Treatment Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Myasthenia Gravis Market  Analysis and Forecasts, 2017–2027

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Industry Development (Acquisition, Collaboration, Merger, Approvals etc.)

        5.3. Epidemiology of Myasthenia Gravis By Country/Sub-region

        5.4. Regulatory Scenario

    6. Global Myasthenia Gravis Market  Analysis and Forecasts, by Treatment Type

        6.1. Introduction & Definition

            6.1.1. Key Findings / Developments

        6.2. Global Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

            6.2.1. Drug Treatment

                6.2.1.1. Cholinesterase Inhibitors

                6.2.1.2. Chronic Immunomodulators

                6.2.1.3. Monoclonal Antibodies

            6.2.2. Rapid Immunotherapies

                6.2.2.1. Plasmapheresis

                6.2.2.2. Intravenous Immunoglobulin (Ivlg)

            6.2.3. Thymectomy

        6.3. Global Myasthenia Gravis Market Attractiveness by Treatment Type

    7. Global Myasthenia Gravis Market  Analysis and Forecasts, by Region

        7.1. Key Findings

        7.2. Global Myasthenia Gravis Market Value & Volume Forecast by Region

            7.2.1. North America 

            7.2.2. Europe 

            7.2.3. Asia Pacific 

            7.2.4. Latin America 

            7.2.5. Middle East & Africa 

        7.3. Global Myasthenia Gravis Market Attractiveness by Country/Region

    8. North America Myasthenia Gravis Market  Analysis and Forecast

        8.1. Introduction

            8.1.1. Key Findings

        8.2.  North America Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

            8.2.1. Drug Treatment

                8.2.1.1. Cholinesterase Inhibitors

                8.2.1.2. Chronic Immunomodulators

                8.2.1.3. Monoclonal Antibodies

            8.2.2. Rapid Immunotherapies

                8.2.2.1. Plasmapheresis

                8.2.2.2. Intravenous Immunoglobulin (Ivlg)

            8.2.3. Thymectomy

        8.3. North America Myasthenia Gravis Market Value & Volume Forecast by Country, 2017–2027

            8.3.1. U.S.

            8.3.2. Canada

        8.4. North America Myasthenia Gravis Market Attractiveness Analysis 

            8.4.1. By Treatment Type

            8.4.2. By Country

    9. Europe Myasthenia Gravis Market  Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Europe Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

            9.2.1. Drug Treatment

                9.2.1.1. Cholinesterase Inhibitors

                9.2.1.2. Chronic Immunomodulators

                9.2.1.3. Monoclonal Antibodies

            9.2.2. Rapid Immunotherapies

                9.2.2.1. Plasmapheresis

                9.2.2.2. Intravenous Immunoglobulin (Ivlg)

            9.2.3. Thymectomy

        9.3. Europe Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2027

            9.3.1. Germany

            9.3.2. U.K.

            9.3.3. France

            9.3.4. Spain

            9.3.5. Italy

            9.3.6. Rest of Europe

        9.4. Europe Myasthenia Gravis Market Attractiveness Analysis 

            9.4.1. By Treatment Type

            9.4.2. By Country/Sub-region

    10. Asia Pacific Myasthenia Gravis Market  Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Asia Pacific Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

            10.2.1. Drug Treatment

                10.2.1.1. Cholinesterase Inhibitors

                10.2.1.2. Chronic Immunomodulators

                10.2.1.3. Monoclonal Antibodies

            10.2.2. Rapid Immunotherapies

                10.2.2.1. Plasmapheresis

                10.2.2.2. Intravenous Immunoglobulin (Ivlg)

            10.2.3. Thymectomy

        10.3. Asia Pacific Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2027

            10.3.1. China

            10.3.2. Japan

            10.3.3. India

            10.3.4. Australia & New Zealand

            10.3.5. Rest of Asia Pacific

        10.4. Asia Pacific Myasthenia Gravis Market Attractiveness Analysis 

            10.4.1. By Treatment Type

            10.4.2. By Country/Sub-region

    11. Latin America Myasthenia Gravis Market  Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Latin America Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

            11.2.1. Drug Treatment

                11.2.1.1. Cholinesterase Inhibitors

                11.2.1.2. Chronic Immunomodulators

                11.2.1.3. Monoclonal Antibodies

            11.2.2. Rapid Immunotherapies

                11.2.2.1. Plasmapheresis

                11.2.2.2. Intravenous Immunoglobulin (Ivlg)

            11.2.3. Thymectomy

        11.3. Latin America Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2027

            11.3.1. Brazil

            11.3.2. Mexico

            11.3.3. Rest of Latin America

        11.4. Latin America Myasthenia Gravis Market Attractiveness Analysis 

            11.4.1. By Treatment Type

            11.4.2. By Country/Sub-region

    12. Middle East & Africa Myasthenia Gravis Market  Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Middle East & Africa Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

            12.2.1. Drug Treatment

                12.2.1.1. Cholinesterase Inhibitors

                12.2.1.2. Chronic Immunomodulators

                12.2.1.3. Monoclonal Antibodies

            12.2.2. Rapid Immunotherapies

                12.2.2.1. Plasmapheresis

                12.2.2.2. Intravenous Immunoglobulin (Ivlg)

            12.2.3. Thymectomy

        12.3. Middle East & Africa Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2027

            12.3.1. GCC Countries

            12.3.2. South Africa

            12.3.3. Rest of Middle East & Africa

        12.4. Middle East & Africa Myasthenia Gravis Market Attractiveness Analysis 

            12.4.1. By Treatment Type

            12.4.2. By Country/Sub-region

    13. Competition Landscape

        13.1. Market Player – Competition Matrix (By Tier and Size of companies)

        13.2. Market Share Analysis/Ranking By Company (2018)

        13.3. Company Profiles

            13.3.1. Alexion Pharmaceutical Inc. 

                13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.1.2. Growth Strategies

                13.3.1.3. SWOT Analysis. 

            13.3.2. Avadel Pharmaceuticals, PLC. (Flamel Technologies)

                13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.2.2. Growth Strategies

                13.3.2.3. SWOT Analysis. 

            13.3.3. CSL Behring 

                13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.3.2. Growth Strategies

                13.3.3.3. SWOT Analysis. 

            13.3.4. Grifols, S.A. 

                13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.4.2. Growth Strategies

                13.3.4.3. SWOT Analysis. 

            13.3.5. Baxter International, Inc. 

                13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.5.2. Growth Strategies

                13.3.5.3. SWOT Analysis. 

            13.3.6. Shire plc 

                13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.6.2. Growth Strategies

                13.3.6.3. SWOT Analysis. 

            13.3.7. Novartis AG 

                13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.7.2. Growth Strategies

                13.3.7.3. SWOT Analysis. 

            13.3.8. F. Hoffmann-La Roche AG

                13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.8.2. Growth Strategies

                13.3.8.3. SWOT Analysis. 

            13.3.9. Takeda Pharmaceutical Company Limited 

                13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.9.2. Growth Strategies

                13.3.9.3. SWOT Analysis. 

            13.3.10. Valeant Pharmaceuticals International, Inc.

                13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.10.2. Growth Strategies

                13.3.10.3. SWOT Analysis 

    List of Table

    Table 01: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

    Table 02: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Drug Treatment, 2017–2027

    Table 03: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Rapid Immunotherapies, 2017–2027

    Table 04: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Region, 2017–2027

    Table 05: North America Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2017–2027

    Table 06: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

    Table 07: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2017–2027

    Table 08: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2017–2027

    Table 09: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Country, 2017–2027

    Table 10: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

    Table 11: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Drug Treatment, 2017–2027

    Table 12: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Rapid Immunotherapies, 2017–2027

    Table 13: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2017–2027

    Table 14: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

    Table 15: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2017–2027

    Table 16: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2017–2027

    Table 17: Latin America Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017–2027

    Table 18: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

    Table 19: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2017–2027

    Table 20: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2017–2027

    Table 21: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2017–2027

    Table 22: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

    Table 23: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2017–2027

    Table 24: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2017–2027

    List of Figure

    Figure 01: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

    Figure 02: Market Value Share By Region 

    Figure 03: Market Value Share By Treatment 

    Figure 04: Market Value Share By Rapid Immunotherapies 

    Figure 05: Market Value Share By Drug Treatment 

    Figure 06: Global Myasthenia Gravis Market Value Share Analysis, Treatment, 2018 and 2027

    Figure 07: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, by Drug Treatment

    Figure 08: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Rapid Immunotherapies

    Figure 09: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Thymectomy

    Figure 10: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Cholinesterase Inhibitors

    Figure 11: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Chronic Immunomodulators

    Figure 12: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Monoclonal Antibodies

    Figure 13: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Plasmapheresis

    Figure 14: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Intravenous Immunoglobulin

    Figure 15: Global Myasthenia Gravis Market Attractiveness Analysis, by treatment, 2019–2027

    Figure 16: Global Myasthenia Gravis Market Value Share Analysis, by Region, 2018 and 2027

    Figure 17: Myasthenia Gravis Market Attractiveness Analysis, by Region

    Figure 18: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

    Figure 19: North America Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 20: North America Myasthenia Gravis Market Attractiveness Analysis, by Country

    Figure 21: North America Myasthenia Gravis Market Value Share Analysis, by Country, 2018 and 2027

    Figure 22: North America Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 23: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

    Figure 24:  Europe Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 25: Europe Myasthenia Gravis Market Attractiveness Analysis, by Country, 2019–2027

    Figure 26: Europe Myasthenia Gravis Market Value Share Analysis, by Country, 2018 and 2027

    Figure 27: Europe Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 28: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

    Figure 29: Asia Pacific Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 30: Asia Pacific Myasthenia Gravis Market Attractiveness Analysis, by Country

    Figure 31: Asia Pacific Myasthenia Gravis Market Value Share Analysis, by Country, 2018 and 2027

    Figure 32: Asia Pacific Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 33: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

    Figure 34: Latin America Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 35: Latin America Myasthenia Gravis Market Attractiveness Analysis, by Country/Sub-region

    Figure 36: Latin America Myasthenia Gravis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 37: Latin America Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 38: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

    Figure 39:  Middle East & Africa Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 40: Middle East & Africa Myasthenia Gravis Market Attractiveness Analysis, by Country

    Figure 41: Middle East & Africa Myasthenia Gravis Market Value Share Analysis, by Country, 2018 and 2027

    Figure 42: Middle East & Africa Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

    Figure 43: Alexion Pharmaceutical Inc. Revenue (US$ Mn) & Y-o-Y Growth (%)

    Figure 44: Alexion Pharmaceutical Inc. Research & Development Expenses

    Figure 45: Alexion Pharmaceutical Inc. Breakdown of Net Sales, by Product

    Figure 46: Alexion Pharmaceutical Inc. Breakdown of Net Sales, by Region

    Figure 47: AVADEL PHARMACEUTICALS, PLC. Revenue (US$ Mn) & Y-o-Y Growth (%)

    Figure 48: AVADEL PHARMACEUTICALS, PLC. Long-lived Assets (US$ Mn), by Geographic Region

    Figure 49: AVADEL PHARMACEUTICALS, PLC. Breakdown of Net Sales, by Product

    Figure 50: AVADEL PHARMACEUTICALS, PLC. Net Sales, by Region

    Figure 51: CSL Behring Revenue (US$ Mn) & Y-o-Y Growth (%)

    Figure 52: CSL Behring Research & Development Expenses

    Figure 53: CSL Behring Breakdown of Net Sales, by Product

    Figure 54: CSL Behring Breakdown of Net Sales, by Region

    Figure 55: Grifols, S.A. Revenue (US$ Mn) & Y-o-Y Growth (%)

    Figure 56: Grifols, S.A. Research & Development Expenses

    Figure 57: Grifols, S.A. Breakdown of Net Sales, by Business Segment

    Figure 58: Grifols, S.A. Breakdown of Net Sales, by Region

    Figure 59: Baxter International, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%)

    Figure 60: Baxter International, Inc. Marketing and R&D Expenses

    Figure 61: Baxter International, Inc. Breakdown of Net Sales, by Product

    Figure 62: Baxter International, Inc. Breakdown of Net Sales, by Region

    Figure 63: Shire plc Revenue (US$ Mn) and Y-o-Y Growth (%)

    Figure 64: Shire plc R&D and Marketing Expenses

    Figure 65: Shire plc Breakdown of Net Sales, by Product

    Figure 66: Shire plc Breakdown of Net Sales, by Region

    Figure 67: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%)

    Figure 68: Novartis AG Marketing & Sales, and R&D Expenses

    Figure 69: Novartis AG Breakdown of Net Sales, by Business Segment

    Figure 70: Novartis AG Breakdown of Net Sales, by Region

    Figure 71: F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%)

    Figure 72: F. Hoffmann-La Roche AG Marketing and R&D Expenses

    Figure 73: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division

    Figure 74: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Region

    Figure 75: Takeda Pharmaceutical Company Limited Revenue (US$ Bn) and Y-o-Y Growth (%)

    Figure 76: Takeda Pharmaceutical Company Limited Research And Development Expenses

    Figure 77: Takeda Pharmaceutical Company Limited Breakdown of Net Sales, by Business Segment

    Figure 78: Takeda Pharmaceutical Company Limited Breakdown of Net Sales, by Region

    Figure 79: Valeant Pharmaceuticals International, Inc Revenue (US$ Bn) and Y-o-Y Growth (%)

    Figure 80: Valeant Pharmaceuticals International, Inc Marketing and R&D Expenses

    Figure 81: Valeant Pharmaceuticals International, Inc Breakdown of Net Sales, by Region

    Figure 82: Valeant Pharmaceuticals International, Inc Breakdown of Net Sales, by Business Segment

Copyright © Transparency Market Research, Inc. All Rights reserved

Myasthenia Gravis Market

Schedule a Call